Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1

Background— Preeclampsia is characterized clinically by hypertension and proteinuria. Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 [VEGFR-1]) and soluble endoglin (sEng) are elevated in preeclampsia, and their administration to pregnant rats elicits preeclampsia-like symptoms. Heme oxygenase-1 (HO-1) and its metabolite carbon monoxide (CO) exert protective effects against oxidative stimuli. Thus, we hypothesized that HO-1 upregulation may offer protection against preeclampsia by inhibiting sFlt-1 and sEng release. Methods and Results— Preeclamptic villous explants secreted high levels of sFlt-1 and sEng. Adenoviral overexpression of HO-1 in endothelial cells inhibited VEGF-mediated sFlt-1 release and interferon-&ggr;– and tumor necrosis factor-&agr;–induced sEng release, whereas HO-1 inhibition potentiated sFlt-1 and sEng production from endothelial cells and placental villous explants. Consistent with these findings, mice lacking HO-1 produced higher levels of sFlt-1 and sEng compared with wild-type mice. Using selective ligands (VEGF-E and placental growth factor) and a receptor-specific inhibitor (SU-1498), we demonstrated that VEGF-induced sFlt-1 release was VEGFR-2 dependent. Furthermore, CO-releasing molecule-2 (CORM-2) or CO decreased sFlt-1 release and inhibited VEGFR-2 phosphorylation. Treatment of endothelial cells with statins upregulated HO-1 and inhibited the release of sFlt-1, whereas vitamins C and E had no effect. Conclusions— The present study demonstrates that the HO-1/CO pathway inhibits sFlt-1 and sEng release, providing compelling evidence for a protective role of HO-1 in pregnancy, and identifies HO-1 as a novel target for the treatment of preeclampsia.

[1]  V. Adhami,et al.  Constitutive Overexpression of Nrf2-dependent Heme Oxygenase-1 in A549 Cells Contributes to Resistance to Apoptosis Induced by Epigallocatechin 3-Gallate* , 2006, Journal of Biological Chemistry.

[2]  Y. Zhai,et al.  Basal Rather Than Induced Heme Oxygenase-1 Levels Are Crucial in the Antioxidant Cytoprotection1 , 2006, The Journal of Immunology.

[3]  D. Mukhopadhyay,et al.  Direct Evidence for Endothelial Vascular Endothelial Growth Factor Receptor-1 Function in Nitric Oxide–Mediated Angiogenesis , 2006, Circulation research.

[4]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[5]  C. Graham,et al.  Carbon monoxide inhibits hypoxia/reoxygenation-induced apoptosis and secondary necrosis in syncytiotrophoblast. , 2006, The American journal of pathology.

[6]  Takamitsu Nakamura,et al.  Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. , 2006, Journal of the American College of Cardiology.

[7]  E. Gratacós,et al.  Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. , 2006, American journal of obstetrics and gynecology.

[8]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[9]  Caroline A Crowther,et al.  Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study , 2006, BMJ : British Medical Journal.

[10]  L. Poston,et al.  Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial , 2006, The Lancet.

[11]  A. Sepulveda,et al.  Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1–dependent pathway , 2005, The Journal of experimental medicine.

[12]  M. Cunningham,et al.  Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. , 2005, Birth defects research. Part A, Clinical and molecular teratology.

[13]  R. Ness,et al.  Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. , 2005, American journal of obstetrics and gynecology.

[14]  F. Azizieh,et al.  Maternal Cytokine Production Patterns in Women with Pre‐eclampsia , 2005, American journal of reproductive immunology.

[15]  C. Hernández-Guerrero,et al.  The Predominant Th1 Cytokine Profile in Maternal Plasma of Preeclamptic Women Is Not Reflected in the Choriodecidual and Fetal Compartments , 2005, The Journal of the Society for Gynecologic Investigation: JSGI.

[16]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[17]  A. Scialli,et al.  Statin drugs and congenital anomalies , 2005, American journal of medical genetics. Part A.

[18]  Graeme N. Smith,et al.  HO in pregnancy. , 2005, Free radical biology & medicine.

[19]  F. Lyall,et al.  Heme oxygenase expression in cultured human trophoblast cells during in vitro differentiation: effects of hypoxia. , 2005, Placenta.

[20]  K. Nicolaides,et al.  Placental Expression of Interferon-γ (IFN-γ) and Its Receptor IFN-γR2 Fail to Switch from Early Hypoxic to Late Normotensive Development in Preeclampsia , 2005 .

[21]  R. Romero,et al.  Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[22]  K. Erdmann,et al.  The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. , 2004, Free radical biology & medicine.

[23]  Asif Ahmed,et al.  Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia , 2004, Circulation research.

[24]  J. Shyy,et al.  Simvastatin Induces Heme Oxygenase-1: A Novel Mechanism of Vessel Protection , 2004, Circulation.

[25]  N. Berkane,et al.  Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. , 2004, Clinical chemistry.

[26]  N. Sattar,et al.  Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? , 2004, Atherosclerosis.

[27]  D. Stevenson,et al.  End-tidal Breath Carbon Monoxide Measurements are Lower in Pregnant Women with Uterine Contractions , 2004, Journal of Perinatology.

[28]  D. Stevenson,et al.  End Tidal Carbon Monoxide Levels are Lower in Women with Gestational Hypertension and Pre-eclampsia , 2004, Journal of Perinatology.

[29]  Patty J. Lee,et al.  Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis* , 2004, Journal of Biological Chemistry.

[30]  D. Charnock-Jones,et al.  Secretion of Tumor Necrosis Factor- (cid:1) from Human Placental Tissues Induced by Hypoxia-Reoxygenation Causes Endothelial Cell Activation in Vitro A Potential Mediator of the Inflammatory Response in Preeclampsia , 2004 .

[31]  B. Klapp,et al.  Introducing a mouse model for pre‐eclampsia: adoptive transfer of activated Th1 cells leads to pre‐eclampsia‐like symptoms exclusively in pregnant mice , 2004, European journal of immunology.

[32]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[33]  J. Kupiec-Weglinski,et al.  Heme oxygenase system in ischemia and reperfusion injury. , 2003, Annals of transplantation.

[34]  S. Cnattingius,et al.  Adverse pregnancy outcomes in snuff users. , 2003, American journal of obstetrics and gynecology.

[35]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.

[36]  Gillian Smith,et al.  Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. , 2003, The Journal of investigative dermatology.

[37]  B. Klapp,et al.  Heme Oxygenases in Pregnancy II: HO‐2 is Downregulated in Human Pathologic Pregnancies , 2003, American journal of reproductive immunology.

[38]  E. Głowacka,et al.  Lymphocyte subset distribution and cytokine secretion in third trimester decidua in normal pregnancy and preeclampsia. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[39]  E. Seely,et al.  Insulin resistance and its potential role in pregnancy-induced hypertension. , 2003, The Journal of clinical endocrinology and metabolism.

[40]  Y. Taketani,et al.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.

[41]  R. Kalluri,et al.  Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria* , 2003, The Journal of Biological Chemistry.

[42]  S. Shibahara,et al.  Bach1 Functions as a Hypoxia-inducible Repressor for the Heme Oxygenase-1 Gene in Human Cells* , 2003, The Journal of Biological Chemistry.

[43]  L. Vatten,et al.  Intrauterine Exposure to Preeclampsia and Adolescent Blood Pressure, Body Size, and Age at Menarche in Female Offspring , 2003, Obstetrics and gynecology.

[44]  D. Lawson,et al.  Effects of chronic administration of a heme oxygenase substrate or inhibitor on progression of the estrous cycle, pregnancy and lactation of Sprague-Dawley rats. , 2002, Life sciences.

[45]  Yi-peng Wang,et al.  Expression of endogenous heme oxygenase on surface of placental trophoblasts of pregnant women with intrauterine growth retardation of the fetus. , 2002, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA.

[46]  C. Graham,et al.  Heme oxygenase activity in placenta: direct dependence on oxygen availability. , 2002, American journal of physiology. Heart and circulatory physiology.

[47]  R. Busuttil,et al.  A novel strategy against ischemia and reperfusion injury: cytoprotection with heme oxygenase system. , 2002, Transplant immunology.

[48]  K. Yoneyama,et al.  Relation Between Adenosine and T‐helper 1/T‐helper 2 Imbalance in Women With Preeclampsia , 2002, Obstetrics and gynecology.

[49]  K. Alitalo,et al.  Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. , 2002, The American journal of pathology.

[50]  P. Sarathchandra,et al.  Carbon Monoxide-Releasing Molecules: Characterization of Biochemical and Vascular Activities , 2002, Circulation research.

[51]  J. Oyama,et al.  Gene Therapy Strategy for Long-Term Myocardial Protection Using Adeno-Associated Virus-Mediated Delivery of Heme Oxygenase Gene , 2002, Circulation.

[52]  B. Bussolati,et al.  Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. , 2001, The American journal of pathology.

[53]  J. Pell,et al.  Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births , 2001, The Lancet.

[54]  James L. Park,et al.  Heme oxygenase-1 protects against vascular constriction and proliferation , 2001, Nature Medicine.

[55]  F. Lyall,et al.  Heme oxygenase expression in human placenta and placental bed: reduced expression of placenta endothelial HO‐2 in preeclampsia and fetal growth restriction , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  James J. Walker,et al.  Pre-eclampsia , 2000, The Lancet.

[57]  D. Stevenson,et al.  End-tidal carbon monoxide measurements in women with pregnancy-induced hypertension and preeclampsia. , 2000, American journal of obstetrics and gynecology.

[58]  Asif Ahmed,et al.  Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids , 2000, Laboratory Investigation.

[59]  Shakil Ahmad,et al.  Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. , 2000, Placenta.

[60]  M. Krohn,et al.  Urinary cotinine concentration confirms the reduced risk of preeclampsia with tobacco exposure. , 1999, American journal of obstetrics and gynecology.

[61]  A. Choi,et al.  Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. , 1999, The Journal of clinical investigation.

[62]  A. Ahmed,et al.  Hemeoxygenase-1 inhibits human myometrial contractility via carbon monoxide and is upregulated by progesterone during pregnancy. , 1998, The Journal of clinical investigation.

[63]  F. Carraro,et al.  Hypoxia affects cytokine production and proliferative responses by human peripheral mononuclear cells , 1997, Journal of cellular physiology.

[64]  S. Tonegawa,et al.  Reduced stress defense in heme oxygenase 1-deficient cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Tonegawa,et al.  Heme oxygenase 1 is required for mammalian iron reutilization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[66]  W. P. Stephenson,et al.  Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. , 1996, Reproductive toxicology.

[67]  C. Freyssinges,et al.  Simvastatine et grossesse , 1996 .

[68]  P. Baker,et al.  Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients With Preeclampsia , 1995, Obstetrics and gynecology.

[69]  R. Robertson,et al.  Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. , 1983, Teratology.

[70]  H. Marver,et al.  Microsomal heme oxygenase. Characterization of the enzyme. , 1969, The Journal of biological chemistry.

[71]  S. Thung.  Urinary Placental Growth Factor and Risk of Preeclampsia , 2006 .

[72]  D. Haig,et al.  Angiogenic factors in the pathogenesis of preeclampsia. , 2005, Current topics in developmental biology.

[73]  K. Nicolaides,et al.  Placental expression of interferon-gamma (IFN-gamma) and its receptor IFN-gamma R2 fail to switch from early hypoxic to late normotensive development in preeclampsia. , 2005, The Journal of clinical endocrinology and metabolism.

[74]  P. Taylor,et al.  J Soc Gynecol Investig , 2005 .

[75]  S. Macdonald-Goodfellow,et al.  Relationship between tissue damage and heme oxygenase expression in chorionic villi of term human placenta. , 2003, American journal of physiology. Heart and circulatory physiology.

[76]  Asif Ahmed,et al.  Induction of Placental Heme Oxygenase-1 Is Protective Against TNFα-induced Cytotoxicity and Promotes Vessel Relaxation , 2000, Molecular medicine.

[77]  Asif Ahmed.  Heparin-binding angiogenic growth factors in pregnancy , 1997 .

[78]  M. Ducrocq,et al.  [Simvastatin and pregnancy]. , 1996, The´rapie (Paris).

[79]  R. Mayer,et al.  Induction of kidney heme oxygenase-1 (HSP32) mRNA and protein by ischemia/reperfusion: possible role of heme as both promotor of tissue damage and regulator of HSP32. , 1993, The Journal of pharmacology and experimental therapeutics.

[80]  R. Tyrrell,et al.  Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. , 1989, Proceedings of the National Academy of Sciences of the United States of America.